Cookson J C, Kennedy N M, Gribbon D
Int Clin Psychopharmacol. 1986 Jul;1 Suppl 1:41-51.
A one year double-blind trial of haloperidol decanoate and fluphenazine decanoate was conducted in nineteen out-patients who had previously received at least one year's treatment with fluphenazine decanoate and were already overweight, as judged by a Body Mass Index of 25+. Although the difference was not statistically significant, patients treated with haloperidol decanoate showed a trend to less weight gain than patients who continued on fluphenazine decanoate, even though the haloperidol to fluphenazine dose ratio was 4:1. No statistically significant changes in mental state were observed and the incidence of extrapyramidal side-effects in the two treatment groups was similar.
对19名门诊患者进行了为期一年的癸酸氟哌啶醇和癸酸氟奋乃静双盲试验。这些患者此前至少接受过一年的癸酸氟奋乃静治疗，根据体重指数（BMI）≥25判断，他们已经超重。尽管差异无统计学意义，但接受癸酸氟哌啶醇治疗的患者体重增加趋势低于继续使用癸酸氟奋乃静的患者，即便癸酸氟哌啶醇与癸酸氟奋乃静的剂量比为4:1。未观察到精神状态有统计学意义的变化，且两个治疗组锥体外系副作用的发生率相似。
